137 related articles for article (PubMed ID: 17551312)
1. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.
Koukourakis MI; Mavanis I; Kouklakis G; Pitiakoudis M; Minopoulos G; Manolas C; Simopoulos C
Am J Clin Oncol; 2007 Jun; 30(3):315-8. PubMed ID: 17551312
[TBL] [Abstract][Full Text] [Related]
2. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK
Nat Med; 2004 Feb; 10(2):145-7. PubMed ID: 14745444
[TBL] [Abstract][Full Text] [Related]
4. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
[TBL] [Abstract][Full Text] [Related]
5. Regression of a subfoveal choroidal metastasis of colorectal carcinoma after intravitreous bevacizumab treatment.
Kuo IC; Haller JA; Maffrand R; Sambuelli RH; Reviglio VE
Arch Ophthalmol; 2008 Sep; 126(9):1311-3. PubMed ID: 18779499
[No Abstract] [Full Text] [Related]
6. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
7. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
8. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
9. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
10. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
11. Bevacizumab in the treatment of colorectal cancer.
Cilley JC; Barfi K; Benson AB; Mulcahy MF
Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
15. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
Franson PJ; Lapka DV
Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
18. [Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy].
Antoniak K; Nowak JZ
Postepy Hig Med Dosw (Online); 2007 May; 61():320-30. PubMed ID: 17554235
[TBL] [Abstract][Full Text] [Related]
19. Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.
Bohndiek SE; Kettunen MI; Hu DE; Brindle KM
Cancer Res; 2012 Feb; 72(4):854-64. PubMed ID: 22223844
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Hurwitz HI; Honeycutt W; Haley S; Favaro J
Clin Colorectal Cancer; 2006 May; 6(1):66-9. PubMed ID: 16796794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]